.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,611,724

« Back to Dashboard

Claims for Patent: 7,611,724

Title:Method of producing FR901228
Abstract:Depsipeptides and congeners thereof are disclosed having structure (I), wherein m, n, p, q, X, R1, R2 and R3 are as defined herein. These compounds, including FR901228, have activity as, for example, immunosuppressants, as well as for the prevention or treatment of patients suffering or at risk of suffering from inflammatory, autoimmune or immune system-related diseases including graft-versus-host disease and enhancement of graft/tissue survival following transplant. Also provided are methods for inhibiting lymphocyte activation, proliferation, and/or suppression of IL-2 secretion. Also provided are crystalline forms of FR901228, e.g., type A and type B crystalline forms of FR901228.
Inventor(s): Ueda; Satoshi (Chuo-ku, JP), Watamoto; Yoko (Chuo-ku, JP), Tsuboi; Masaru (Chuo-ku, JP), Kanda; Munekazu (Chuo-ku, JP), Higaki; Tomoji (Chuo-ku, JP), Matsuda; Mitsunori (Chuo-ku, JP)
Assignee: Astellas Pharma Inc. (Tokyo, JP)
Application Number:12/396,773
Patent Claims: 1. A type A crystalline form of compound FR901228: ##STR00002##

2. The type A crystalline form of claim 1 obtained from an ethanol/water mixture.

3. A crystalline form of compound FR901228: ##STR00003## which crystalline form is characterized by a powder X-ray diffraction pattern substantially similar to FIG. 3.

4. A composition comprising a type A crystalline form of compound FR901228: ##STR00004## wherein the composition is characterized by having one or more peaks in its powder X-ray diffraction pattern selected from those at about 9.6, about 13.6, about 14.6, and about 17.4 degrees 2-theta.

5. The composition of claim 4, wherein the composition is characterized by having two or more peaks in its powder X-ray diffraction pattern selected from those at about 9.6, about 13.6, about 14.6, and about 17.4 degrees 2-theta.

6. The composition of claim 4, wherein the composition is characterized by having three or more peaks in its powder X-ray diffraction pattern selected from those at about 9.6, about 13.6, about 14.6, and about 17.4 degrees 2-theta.

7. The composition of claim 4, wherein the composition is characterized by having four peaks in its powder X-ray diffraction pattern selected at about 9.6, about 13.6, about 14.6, and about 17.4 degrees 2-theta.

8. The type A crystalline form of claim 1 obtained from an acetone/water mixture.

9. The composition of claim 4 with a powder X-ray diffraction pattern substantially similar to FIG. 4.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc